title: Will the lessons from primary aldosteronism change the treatment of hypertension and left ventricular hypertrophy?
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Auchus
authors.forename: Mark H
authors.initials: MH
authors.lastname: Drazner
mesh_terms: D000315:Adrenalectomy; D001794:Blood Pressure / Q000187:drug effects; D015331:Cohort Studies; D015897:Comorbidity; D005500:Follow-Up Studies; D006801:Humans; D006929:Hyperaldosteronism / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*; D006973:Hypertension / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology / Q000628:therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D015995:Prevalence; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone